On Monday, Taysha Gene Therapies Inc (NASDAQ: TSHA) opened higher 8.67% from the last session, before settling in for the closing price of $1.50. Price fluctuations for TSHA have ranged from $1.19 to $4.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 129.39% annually for the last half of the decade. Company’s average yearly earnings per share was noted 61.72% at the time writing. With a float of $158.49 million, this company’s outstanding shares have now reached $186.96 million.
In an organization with 52 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 89.73%, operating margin of -603.4%, and the pretax margin is -888.18%.
Taysha Gene Therapies Inc (TSHA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Taysha Gene Therapies Inc is 22.67%, while institutional ownership is 73.65%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares. Before that another transaction happened on Nov 17 ’23, when Company’s 10% Owner bought 100,000 for $1.63, making the entire transaction worth $163,000. This insider now owns 16,566,667 shares in total.
Taysha Gene Therapies Inc (TSHA) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.93 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.17) by -0.76. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 61.72% per share during the next fiscal year.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Check out the current performance indicators for Taysha Gene Therapies Inc (TSHA). In the past quarter, the stock posted a quick ratio of 5.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.87, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Let’s dig in a bit further. During the last 5-days, its volume was 7.87 million. That was better than the volume of 2.44 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 41.44%. Additionally, its Average True Range was 0.13.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 24.44%, which indicates a significant decrease from 50.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 101.08% in the past 14 days, which was higher than the 74.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9666, while its 200-day Moving Average is $2.3863. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $1.6900. Second resistance stands at $1.7500. The third major resistance level sits at $1.8500. If the price goes on to break the first support level at $1.5300, it is likely to go to the next support level at $1.4300. The third support level lies at $1.3700 if the price breaches the second support level.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are currently 204,943K shares outstanding in the company with a market cap of 352.87 million. Presently, the company’s annual sales total 15,450 K according to its annual income of -111,570 K. Last quarter, the company’s sales amounted to 1,110 K and its income totaled -20,930 K.
